CAR-T cell compositions, methods of use thereof
AssigneeAugusta University Research Institute, Inc.
InventorsYukai He, Leidy D. Caraballo Galva, Xiaotao Jiang
Life of this patent
Estimating the term…
Abstract
Chimeric antigen receptor T cell (CARTs) compositions and methods of their use are provided. One embodiment provides a chimeric antigen receptor T cell composition including 8F8 chimeric antigen receptor T cells. Another embodiment provides a chimeric antigen receptor T cell composition including 6G11 chimeric antigen receptor T cells. Still another embodiment provide a chimeric antigen receptor T cell composition including 12D7 chimeric antigen receptor T cells. The disclosed CARTs can be used to treat cancer, for example hepatocellular carcinoma.
Claims20
A chimeric antigen receptor comprising an extracellular domain comprising an antigen binding domain that immunospecifically binds to Glypican 3 (GPC3), the antigen binding domain comprising a light chain variable region comprising the three complementarity determining regions (CDRs) of SEQ ID NO:9 and heavy chain variable region comprising the three CDRs of SEQ ID NO:11.
A chimeric antigen receptor comprising an extracellular domain comprising an antigen binding domain that immunospecifically binds to Glypican 3 (GPC3) linked to a hinge domain linked to transmembrane domain linked to an intracellular domain, wherein
- the antigen binding domain comprises a light chain variable domain comprising the three complementarity determining regions (CDRs) of SEQ ID NO:9 and heavy chain variable domain comprising the three CDRs of SEQ ID NO:11,
- the hinge domain comprises a hinge domain from CD8,
- the transmembrane domain comprises the transmembrane domain of CD28, and
- the intracellular domain comprises 4-1BB and CD3ζ chain signaling domains.
Dependencies are inferred from the claim text.